Drug Profile
Research programme: oral antibody therapeutics - Precigen Inc/Merck
Alternative Names: Antibody expression project - Precigen Inc/MerckLatest Information Update: 11 Feb 2020
Price :
$50
*
At a glance
- Originator ActoGeniX
- Developer Merck & Co; Precigen Inc
- Class Antibodies; Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Belgium (PO, Capsule)
- 12 Nov 2012 ActoGeniX and Merck & Co agree to co-develop oral antibody therapeutics in Belgium for an undisclosed indication